Hair loss affects nearly half of all men and up to a third of women worldwide, yet the treatments available to them have barely changed in decades. Now, a comprehensive review published in Materials Today Bio argues that a quiet revolution is underway at the intersection of materials science and dermatology: intelligent microneedle systems capable of delivering combinations of drugs directly to the hair follicle, on demand, with precision that conventional creams and pills simply cannot match.

The review, authored by Liang Lan, Yiyu Wang, Bin Xue, and Peng Chen, synthesizes a rapidly expanding body of preclinical evidence on microneedle-mediated delivery for androgenetic alopecia, the most common form of hair loss. Their central thesis is provocative: the future of hair regeneration lies not in new drugs alone, but in smarter delivery platforms that treat the scalp as a complex, dynamic microenvironment requiring multi-pathway intervention.

The biological case for this approach is compelling. Androgenetic alopecia is classically understood as a hormonal disorder driven by dihydrotestosterone, a potent androgen produced when the enzyme type II 5α-reductase converts testosterone in the scalp. Dihydrotestosterone binds to androgen receptors in dermal papilla cells, shortening the growth phase of the hair cycle, prolonging the resting phase, and progressively miniaturizing follicles until they produce only fine, nearly invisible hairs. But the authors emphasize that this picture is increasingly recognized as incomplete. Oxidative stress, chronic low-grade inflammation, impaired blood supply, mitochondrial dysfunction, senescence of dermal papilla cells, and insufficient activation of hair follicle stem cells all conspire to degrade the regenerative niche surrounding each follicle. A therapy that only blocks androgen signaling, they argue, addresses just one thread of a tangled pathological web.

Existing approved treatments illustrate the problem. Topical minoxidil requires daily application, suffers from poor bioavailability, and frequently causes scalp irritation, itching, and unwanted facial hair growth. Oral finasteride, while effective at suppressing dihydrotestosterone, carries risks of sexual dysfunction, mood changes, and teratogenic effects in women of childbearing potential. Low-dose oral minoxidil, increasingly used off-label, can produce fluid retention, rapid heartbeat, and dose-dependent hypertrichosis. The recently approved Janus kinase inhibitor baricitinib for alopecia areata brings warnings about infections, thromboembolic events, and laboratory abnormalities. Even adjunct options such as platelet-rich plasma injections, laser therapy, and transplantation are constrained by high cost, protocol variability, or invasiveness. Against this backdrop, the reviewers position microneedles as a third-generation transdermal platform that could thread the needle—literally—between efficacy and safety.

Microneedles are arrays of micron-scale projections, typically several hundred micrometers to roughly a millimeter long, that painlessly breach the stratum corneum, the tough outermost layer of skin that blocks most topical drugs from reaching the deep follicular structures. The review categorizes four core designs. Solid microneedles, including the familiar dermarollers, puncture the skin to create microchannels through which subsequently applied drugs can diffuse; they also generate mechanical microinjury that appears to activate wound-healing cascades, stimulate growth factor release, and engage the Wnt/β-catenin signaling pathway that governs the transition of follicles from resting to growing phases. Hollow microneedles function like miniature hypodermic needles, allowing precisely controlled infusion of liquid formulations—one preclinical system used ultrasound-assisted acoustic cavitation to markedly enhance transdermal delivery of finasteride. Dissolvable microneedles, cast from biodegradable polymers such as hyaluronic acid and polyvinylpyrrolidone, embed their drug payload directly in the needle tips, which dissolve in interstitial fluid to deposit medication exactly where it is needed, eliminating sharps waste and simplifying self-administration. Hydrogel-forming microneedles, meanwhile, swell after insertion to form hydrated diffusion conduits connected to a reservoir, enabling sustained release over days or longer.

The elegance of these systems lies in their tunability. By adjusting polymer composition, crosslinking density, needle geometry, and drug distribution between tips and backing layers, engineers can program rapid, sustained, or staged release. Core–shell and multilayer architectures can deliver an anti-inflammatory agent immediately while a degrading core dispenses growth factors or follicle activators over subsequent days. Nanocarriers embedded within the needles—liposomes, polymeric nanoparticles, lipid–polymer hybrids—protect fragile payloads such as microRNAs, peptides, and extracellular vesicles from degradation while prolonging their retention near follicular units. In one notable example cited in the review, lipid–polymer hybrid nanoparticles encapsulating miR-218, a microRNA that activates Wnt/β-catenin signaling, were loaded into dissolving microneedles and promoted hair regeneration in experimental models.

Perhaps the most striking advances involve nanozymes, artificial enzyme mimics that catalytically destroy reactive oxygen species accumulating around stressed follicles. Machine-learning-assisted screening identified a manganese thiophosphate mimic of superoxide dismutase with an inhibitory concentration twelvefold lower than most reported alternatives, and microneedle patches carrying this material cleared scalp oxidative stress and stimulated regrowth in mouse models. Ceria nanozymes delivered via microneedles combined antioxidant activity with the mechanical stimulation of insertion, boosting vascular endothelial growth factor expression and angiogenesis. Platinum nanozyme patches performed a cascade reaction, converting destructive reactive oxygen species into molecular oxygen, which in turn elevated oxidative phosphorylation in hair follicle stem cells and drove their differentiation toward hair lineage cells. Copper oxide nanozymes, synthesized through green chemistry routes, similarly scavenged hydroxyl and superoxide radicals while promoting vascular regeneration. In these preclinical studies, the microneedle systems outperformed standard minoxidil in duration of effect and dosing frequency.

Growth factor and cell-based strategies round out the therapeutic arsenal. A borate-modified recombinant collagen XVII system delivering insulin-like growth factor 1 achieved 83 percent hair coverage in the experimental model it was tested in, leveraging collagen XVII’s known role in follicular aging. Temperature-responsive microneedles encapsulating platelet-rich plasma gels sustained the release of multiple growth factors for four to six days. Hydrogel microneedles co-delivering vascular endothelial growth factor alongside ritlecitinib-loaded nanoparticles paired pro-angiogenic support with prolonged immune modulation. Extracellular vesicles from mesenchymal stem cells, hypoxia-conditioned vesicles carrying selenium nanoparticles, and even magnetic intracellular vesicles from dental pulp stem cells have all been packaged into microneedle platforms, each addressing inflammation, vascularization, oxidative stress, and androgen damage simultaneously.

The reviewers are refreshingly candid about a scientific caveat that often goes unexamined in this literature: combination does not automatically equal synergy. Many reported systems demonstrate multi-pathway or additive benefits rather than true pharmacological synergy, and distinguishing between the two requires rigorous single-component controls and quantitative combination analysis—experiments that most published studies have not yet performed. They also caution that reactive oxygen species play legitimate signaling roles in tissue repair, so indiscriminate antioxidant depletion could backfire, and that the long-term biodegradation and immunological safety of nanozymes in the scalp remain uncharacterized.

Translational hurdles are substantial. Hair-bearing, curved, sebum-covered scalps complicate patch adhesion and insertion uniformity in ways that smooth skin does not. Dissolvable needles are humidity-sensitive and can lose payload uniformity in storage. Hydrogel systems face complex fabrication, batch-to-batch variability, and high costs. Dose accuracy, sterilization compatibility, scalable manufacturing, and regulatory pathways all demand attention before these systems reach the clinic. Yet the direction of travel is unmistakable. The review’s most forward-looking section describes closed-loop theranostic systems in which hydrogel microneedles simultaneously deliver drugs and sample interstitial fluid, detecting pH shifts, cytokines, oxidative stress markers, or drug concentrations, and feeding that data to actuation modules that adjust dosing in real time. Such systems would transform hair loss treatment from a blunt, trial-and-error exercise into personalized, feedback-controlled therapy tailored to an individual’s follicular microenvironment as it evolves.

For the millions of people whose hairlines recede earlier each decade—a trend the authors link to pollution, lifestyle, and rising psychosocial stress—microneedle patches promise something the current pharmacopeia cannot: painless, self-administered, precisely targeted combination therapy that leaves the rest of the body untouched. The evidence remains preclinical, and the authors insist that efficacy, safety, manufacturability, and clinical value must all be rigorously validated. But if the engineering keeps pace with the biology, the humble patch pressed onto a thinning scalp may become one of the most sophisticated drug delivery platforms in medicine.

Subject of Research: Microneedle-mediated intelligent combination delivery systems for androgenetic alopecia and hair regeneration

Subject of Research: Technology and Engineering

Article Title: Microneedle-mediated intelligent combination delivery for hair regeneration: A comprehensive review of technologies, mechanistic evidence, and translational prospects

Article References: Lan, L., Wang, Y., Xue, B., & Chen, P. (2026). Microneedle-mediated intelligent combination delivery for hair regeneration: A comprehensive review of technologies, mechanistic evidence, and translational prospects. Materials Today Bio, 40, Article 103627. https://doi.org/10.1016/j.mtbio.2026.103627

Image Credits: AI Generated

DOI: 10.1016/j.mtbio.2026.103627

Keywords: androgenetic alopecia, microneedles, drug delivery, hair regeneration, nanozymes, extracellular vesicles, transdermal, minoxidil, finasteride, Wnt/β-catenin

Cite Scienmag News

APA
MLA
Chicago

Denise Maddox. (September 9, 2026). Microneedle-based combination therapies for hair regeneration: technology, mechanism, translation. Scienmag. https://scienmag.com/microneedle-based-combination-therapies-for-hair-regeneration-technology-mechanism-translation/

Copy citation
Download RIS

Tags: advances in minimally invasive dermatological treatmentsandrogenetic alopecia treatmentandrogenetic alopecia treatment innovationscombination therapies for hair regenerationcombination treatments for hair losshair regeneration therapieshormonal regulation of hair follicleshormone-driven hair loss therapiesintelligent microneedle systemsmaterials science in dermatologymicroenvironmental intervention in hair growthmicroneedle drug deliverymicroneedle drug delivery for hair lossmicroneedle technology in hair loss therapymulti-pathway hair loss interventionsmulti-pathway hair regeneration strategiesprecision drug delivery for hair growthprecision drug delivery systemspreclinical hair regeneration researchpreclinical studies on microneedlesscalp microenvironment modulationtargeted scalp drug delivery